Most of the FGFR1 inhibitors lack good kinase selectivity, its efficiency can be affected when high intracellular concentration of ATP exists, and they also result in a variety of side effects like nausea, weakness, hyperphosphataemia, and elevated blood pressure during clinical trial [15, 29]. The gene discussed is FGFR1; the disease is hyperphosphatemia.